In summary, these results suggest that, at least in our cohort of advanced NSCLC patients, elevated baseline absolute cell counts of slan+-monocytes, pDCs, and NK cells (including the CD56dimCD16+ NK cell subset), as well as low expression levels of PD-L1 on cDC1s, may function as predictive biomarkers for a positive response to ICI monotherapy. The gene discussed is CD274; the disease is non-small cell lung carcinoma.